A Phase 3, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine in Children With Sickle Cell Disease Previously Immunized With 23 Valent pneumococcal polysacchride Vaccine.

drug protocol number
B1851013
drug sponsor
Pfizer(Wyeth)
drug study
13-valent Pneumoccocal Conjugate Vaccine
drug trial site
KFSH & RC-R
drug status
Completed
drug phase